 |
 |
Bob Amatadine (symmetrel) is an anticholinergic cmpound (often used to treat flu-like symptoms). It was not intended for anti-parkinsons treatment and there is still some question as to why it helps. I am taking it now to help control dyskinesia in my left foot. Cogentin and benadryl are just two of the many similar drugs. Selegeline (eldepryl) on the other hand, is a monoamine oxidase inhibitor - type B (metabolic enzyme blockade, i.e. the drug reduces the breakdown of dopamine within the brain). Taken with dopamine, selegeline increases dopamine efficacy. Selegeline, too, was not created for Parkinson's, but was originally an anti-depressant. The jury is still out on whether or not selegeline offers neuroprotection, but many neurologists suggest it be taken. The major drawback with taking an MAO inhibitor is that is interacts violently with several routinely-administered medications, such as Demerol (and some foods). Although I have some medical background, I am not a professional in medications, but the NPF has some invaluable information on PD medications at this site http://www.parkinson.org/med4.htm#intro beginning on page 5 and following. Peggy ----- Original Message ----- From: "Bob Allison" <[log in to unmask]> To: "Peggy Willocks" <[log in to unmask]> Sent: Monday, November 24, 2003 8:56 PM Subject: Re: What Is the Best Initial Treatment for PD? > Peggy Thanks for the info; I am reaching a stage where I want to start > medication due to increasing bradykinesia and worsening tremor on one side . > One initial therapy that was not mentioned was amantidine. I am considering > it; any idea amongst a lister or reader as to how amantidine compares to > selegiline? Thanks, Bob > ----- Original Message ----- > From: "Peggy Willocks" <[log in to unmask]> > To: <[log in to unmask]> > Sent: Sunday, November 23, 2003 12:45 PM > Subject: What Is the Best Initial Treatment for PD? > > > > This question often comes up. Here is a qualitative (literature) study > conducted from 1966 to 1999, and was presented in 2002. If anyone has > something more current, please post it in replying here. > > BTW this particular study is pretty comprehensive! It helps explain why my > neuro suggests my continued use of selegeline (eldepryl) > > > > Peggy > > > > > > The Journal of Family Practice . October 2003 . Vol. 52, No. 10 > > > > What is the best initial treatment of Parkinson's disease? > > > > EVIDENCE-BASED ANSWER > > > > No studies clearly demonstrate the best initial treatment for Parkinson's > disease. Levodopa improves motor function in Parkinson's disease; however, > long-term use is associated with irreversible dyskinesias and motor > fluctuations. Compared with placebo, selegiline improves the motor symptoms > of Parkinson's disease and allows a physician to delay the introduction of > levodopa by 9 to 12 months (strength of recommendation [SOR]: A, based on > randomized controlled trials). > > > > Dopamine agonists-alone or combined with levodopa-have fewer associated > dyskinesias and other motor complications but produce lower scores on > activities of daily living and Unified Parkinson's Disease Rating Scale > (UPDRS) when compared with levodopa alone (SOR: A, based on systematic > reviews of randomized controlled trials). Drug choices should be based on > each patient's individual symptoms and response to medication (Table). > > > > EVIDENCE SUMMARY > > > > Five randomized controlled trials have shown improved motor function and > activities of daily living with selegiline vs placebo in early Parkinson's > disease. Two of these trials1, found that selegiline delayed the need for > levodopa for 9 to 12 months. > > > > One large randomized controlled trial showed no difference in disability > scores and an increase in mortality at 5.6 years when comparing selegiline > combined with levodopa to levodopa alone. A re-analysis of this study, as > well as subsequent studies, have not supported this conclusion and found no > increase in mortality in patients with a history of selegiline use. > > > > Two Cochrane reviews found that patients who tolerated the dopamine > agonist bromocriptine-when administered alone or with levodopa-had delayed > dyskinesias and motor complications compared with levodopa alone. There was > no change in off-time with the combination. A large randomized controlled > trial comparing bromocriptine with levodopa demonstrated that at 3 years, > disability scores were lower in the patients initially assigned to > bromocriptine, but the difference was no longer significant at 9 years. > > > > The bromocriptine group in this trial showed a lower incidence of > dyskinesias when data from all patient groups were combined. However, when > moderate to severe cases were analyzed separately, there was no significant > difference. There was no difference in mortality between patients initially > treated with bromocriptine vs levodopa. > > > > Studies of other dopamine agonists show results comparable with > bromocriptine. Lisuride (not available in the US) with rescue levodopa vs > levodopa alone had fewer motor complications at 4 years but lower UPDRS and > activities of daily living scores. Another study comparing lisuride (with or > without levodopa) vs levodopa alone found no difference in motor > complications at 5 years. Studies with cabergoline, pramipexole, and > pergolide-alone or combined with levodopa-vs levodopa alone showed a > decrease in motor complications with the dopamine agonist but lower > activities of daily living and UPDRS scores. > > > > RECOMMENDATIONS FROM OTHERS > > > > In 2002, the American Academy of Neurology published practice parameters > for the initiation of treatment for Parkinson's disease based on literature > from 1966 to 1999. The authors concluded: > > > > selegiline has mild symptomatic benefit and may be tried as initial > therapy, but confers no neuroprotective effect > > either levodopa or a dopamine agonist can be used for the initial > treatment of symptomatic Parkinson's disease > > levodopa has a higher risk of dyskinesias than a dopamine agonist but > superior motor benefits,20 and is less likely to have other side effects > (nausea, hallucinations, somnolence, and edema). > > Jennifer Schreck, MD, Gary Kelsberg, MD, Valley Medical Center Family > Practice Residency, Renton, Wash; Joanne Rich, BSc (Pharm), MLIS, University > of Washington Health Sciences Libraries, Seattle > > > > CLINICAL COMMENTARY > > > > Family physicians play a key role in monitoring Parkinson's. Parkinson's > disease has a profound impact on a patient's physical and psychological > well-being. Difficulties with movement, autonomic nervous system > abnormalities, neuropsychiatric symptoms, and problems with medication > effectiveness and side effects all occur throughout its course. > > > > Consultation with a neurologist skilled in this disorder can be quite > helpful, particularly in younger patients or when the diagnosis is unclear. > The family physician plays a key role in monitoring of the patient's > condition. > > > > Active management of symptoms (and comorbidities as they arise) is crucial > in helping patients maintain their functional status and quality of life. > > > > Randy Ward, MD, Medical College of Wisconsin, Milwaukee > > > > > > > > ---------------------------------------------------------------------- > > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn